CHROMOLOGIC LLC — Department of Defense SBIR Phase I: DHA17-011
CHROMOLOGIC LLC — SBIR Phase I award from Department of Defense.
- Amount
- $149,824
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Topic
- DHA17-011
- Solicitation
- 2017.1
- NAICS
- —
- Place of performance
- CA
- Period
- 2017-09-25 → 2018-04-24
Description
In order to meet the Defense Health Agencys need for addressing the prevention of secondary brain injury from moderate, severe and penetrating traumatic brain injury (TBI), ChromoLogic proposes to develop a cerebral trauma recovery (CereTRec) drug delivery system. In particular, CereTRec aims to treat TBI during prolonged field care (PFC) to stabilize casualties who sustain a moderate-severe TBI. In Phase I, ChromoLogic will develop, formulate, and test CereTRec for in vitro pre-clinical studies. In Phase II, CereTRec will be refined to be tested in large animal or non-human primate pre-clinical models of moderate-severe TBI for efficacy and drug dose.